A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models
- 16 April 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (15), 4093-4106
- https://doi.org/10.1158/1078-0432.ccr-19-4137
Abstract
Purpose: For refractory/relapsed Hodgkin lymphoma (HL) patients (roughly 20% of total cases), few effective therapeutic options exist. Currently, Brentuximab Vedotin (BV), a drug-conjugated anti-CD30 antibody, is one of the most effective approved therapy agents for these patients. However, many patients do not achieve complete remission and ultimately develop BV-resistant disease, -necessitating a more detailed understanding of the molecular circuitry that drives BV sensitivity and the mechanism of BV resistance. Experimental Design: Here, we established a ubiquitin regulator-focused CRISPR library screening platform in HL and carried out a drug sensitization screen against BV to identify genes regulating BV treatment sensitivity. Results: Our CRISPR library screens revealed the ubiquitin-editing enzymes A20 and RBX1 as key molecule effectors that regulate BV sensitivity in HL line L428. A20 negatively regulates NF-κB activity which is required to prevent BV cytotoxicity. In line with these results, the RNA-seq analysis of the BV-resistant single cell clones demonstrated a consistent upregulation of NF-κB signature genes, as well as the ABC transporter gene ABCB1. Mechanically, NF-κB regulates BV treatment sensitivity through mediating ABCB1 expression. Targeting NF-κB activity synergized well with BV in killing HL cell lines, augmented BV sensitivity and overcame BV resistance in vitro and in HL xenograft mouse models. Conclusions: Thus, our identification of this previously unrecognized mechanism provides novel knowledge of possible BV responsiveness and resistance mechanism in HL, as well as leads to promising hypothesis for the development of therapeutic strategies to overcome BV resistance in this disease.Keywords
Other Versions
Funding Information
- NIH (K22 CA197014)
- American Cancer Society (IRG-92-027-21)
- NIH NCI (P30 CA006927)
This publication has 48 references indexed in Scilit:
- Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemiaBMC Cancer, 2012
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomasBlood, 2009
- TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphomaThe Journal of Experimental Medicine, 2009
- TopHat: discovering splice junctions with RNA-SeqBioinformatics, 2009
- Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cellsBMC Cancer, 2008
- Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRILBlood, 2006
- De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signallingNature, 2004
- Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell linesBlood, 2001